Cardiac sympathetic imaging with mIBG in heart failure

JACC Cardiovasc Imaging. 2010 Jan;3(1):92-100. doi: 10.1016/j.jcmg.2009.07.014.

Abstract

Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF.

Publication types

  • Review

MeSH terms

  • 3-Iodobenzylguanidine*
  • Arrhythmias, Cardiac / diagnostic imaging
  • Arrhythmias, Cardiac / etiology
  • Arrhythmias, Cardiac / physiopathology
  • Death, Sudden, Cardiac / etiology
  • Female
  • Heart / diagnostic imaging*
  • Heart / innervation*
  • Heart Failure / complications
  • Heart Failure / diagnostic imaging*
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Heart Failure / therapy
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Radiopharmaceuticals*
  • Risk Assessment
  • Sympathetic Nervous System / diagnostic imaging*
  • Sympathetic Nervous System / physiopathology
  • Tomography, Emission-Computed / methods*
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine